BNB PLUS CORP. — fact timeline

BNB PLUS CORP. issued exercise of Series E Warrants in an aggregate amount of approximately $0.22 million of warrant to an Exchanging Holder for approximately $0.22 million.

“On May 31, 2026, the Company entered into an Inducement Agreement with an Exchanging Holder for an exercise of Series E Warrants in an aggregate amount of approximately $0.22 million.”

BNB PLUS CORP. issued Common Warrants to purchase 2,380,953 shares of Common Stock of warrant to the Purchaser for Gross proceeds from the SPA totaled $2.5 million.

“On May 28, 2026, the Company closed the transaction contemplated by the SPA and sold and issued to the Purchaser, at an offering price of $1.05 per share, 2,380,953 shares of Series B-1 Preferred Stock and Common Warrants to purchase 2,380,953 shares of Common Stock. Gross proceeds from the SPA totaled $2.5 million.”

BNB PLUS CORP. issued 2,380,953 shares of Series B-1 Preferred Stock of preferred stock to the Purchaser for $1.05 per share, $2.5 million gross proceeds.

“On May 28, 2026, the Company closed the transaction contemplated by the SPA and sold and issued to the Purchaser, at an offering price of $1.05 per share, 2,380,953 shares of Series B-1 Preferred Stock and Common Warrants to purchase 2,380,953 shares of Common Stock. Gross proceeds from the SPA totaled $2.5 million.”

BNB PLUS CORP. issued the same number of Series B-2 Prefunded Warrants of warrant to Exchanging Holders for exchange of pre-funded warrants held from 2025 PIPE.

“deliver to the Company all pre-funded warrants issued to the Exchanging Holder in the 2025 PIPE in exchange for the Company issuing the Exchanging Holder the same number of Series B-2 Prefunded Warrants”

BNB PLUS CORP. issued the same number of Series B-2 Preferred Stock of preferred stock to Exchanging Holders for exchange of Common Stock issued in the 2025 PIPE.

“deliver to the Company all shares of Common Stock issued to the Exchanging Holder in the 2025 PIPE and issued in connection with the exercise of the Minimum Percentage of Series E Warrants in exchange for the Company issuing the Exchanging Holder the same number of Series B-2 Preferred Stock”

BNB PLUS CORP. issued 100% of the shares of Common Stock issuable upon conversion of the Series B-1 Preferred Stock of warrant to accredited investors for included in the SPA subscription price.

“and Series F Common Stock Purchase Warrants (the “Common Warrants”) to purchase a number of shares of Common Stock equal to 100% of the shares of Common Stock issuable upon conversion of the Series B-1 Preferred Stock”

BNB PLUS CORP. issued warrant to accredited investors for included in $1.05 per share offering price.

“the Company has agreed to sell and issue to each Purchaser, at an offering price of $1.05 per share, Series B-1 Preferred Stock (defined in Item 5.03 below), and/or Series B-1 Prefunded Preferred Stock Purchase Warrants”

BNB PLUS CORP. issued preferred stock to accredited investors for $1.05 per share, $2.5 million aggregate subscription.

“Pursuant to the SPA, the Company has agreed to sell and issue to each Purchaser, at an offering price of $1.05 per share, Series B-1 Preferred Stock”

BNB PLUS CORP. entered into Warrant Inducement and Exchange Agreement with certain investors who participated in 2025 PIPE (effective 2026-05-26).

“(2) Warrant Inducement and Exchange Agreements (each an “Inducement Agreement”), with certain investors (each an “Exchanging Holder”) who participated in the Company’s private placements that closed on October 3, 2025 and October 23, 2025 (collectively the “2025 PIPE”)”

BNB PLUS CORP. entered into Securities Purchase Agreement with accredited investors valued at up to an aggregate amount of $5 million (effective 2026-05-26).

“On May 26, 2026, BNB Plus Corp., a Delaware corporation (the “Company”), entered into agreements to issue in one or more offerings up to an aggregate amount of $5 million (the “Aggregate Offering Amount”) of the Company’s securities in a convertible preferred equity private placement financing pursuant to: (1) a Securities Purchase Agreement (the “SPA”) with accredited investors (“Purchasers”)”

BNB PLUS CORP.: Created two new series of preferred stock, Series B-1 and Series B-2, via certificates of designation filed with the Secretary of State of Delaware, effective May 26, 2026, designating 5,000,000 shares each from previously undesignated preferred shares (effective 2026-05-26).

“In connection with the Offering, the Company’s Board of Directors (the “Board”) approved a certificate of designation (the “Series B-1 Certificate of Designation”) fixing the voting powers, designations, preferences and rights and the qualifications, limitations or restrictions of Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “Series B-1 Preferred Stock”), a newly created series of preferred stock of the Company, which became effective upon its filing with the Secretary of State of the State of Delaware on May 26, 2026.”

BNB PLUS CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 20, 2026 (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer satisfies the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (col”

BNB PLUS CORP.: Changed company name from Applied DNA Sciences, Inc. to BNB Plus Corp. via an amendment to the amended and restated certificate of incorporation (effective 2025-11-13).

“Effective November 13, 2025, Applied DNA Sciences, Inc. (the “ Company ”) changed its name to BNB Plus Corp., pursuant to an amendment to its amended and restated certificate of incorporation adopted by the Company’s Board of Directors and filed with the Secretary of State of the State of Delaware (the “ Name Change ”).”

BNB PLUS CORP. announced a restructuring with charges of $1.4 million aggregate pre-tax charges for severance payments, employee benefits, and related costs affecting workforce reduction, reduction of 16 employees (approx. 60%) (reduction of the Company’s current workforce by sixteen employees, or approximately 60%).

“On September 30, 2025, the Board of Directors of Applied DNA Sciences, Inc. (the “ Company ”) authorized, and its officers implemented, a restructuring plan pursuant to which the Company will reduce overall operating expenses to focus resources on its previously announced BNB-focused treasury strategy. The restructuring plan includes a reduction of the Company’s current workforce by sixteen employees, or approximately 60%. The Company estimates that it will incur aggregate pre-tax charges of approximately $1.4 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.”

BNB PLUS CORP. issued warrants to purchase Common Stock (the “Advisory Warrants”) equal to 9.5% of the shares of Common Stock outstanding on the date of the closing of the Offering of warrant to Cypress Management LLC.

“issue to the Strategic Advisor five (5) year warrants to purchase Common Stock (the “Advisory Warrants”) equal to 9.5% of the shares of Common Stock outstanding on the date of the closing of the Offering”

BNB PLUS CORP. issued 3,444,164 Series E-2 Warrants (the “Cryptocurrency Common Warrants”) at a per share exercise price of $3.82 of warrant to accredited investors.

“3,444,164 Series E-2 Warrants (the “Cryptocurrency Common Warrants”) at a per share exercise price of $3.82”

BNB PLUS CORP. issued 3,444,164 prefunded warrants (the “Cryptocurrency Prefunded Warrants”) of warrant to accredited investors for offering price of $3.32 per share.

“3,444,164 prefunded warrants (the “Cryptocurrency Prefunded Warrants”), at an offering price of $3.32 per share, to purchase shares of Common Stock at a per share exercise price of $3.82”

BNB PLUS CORP. issued Series E-1 Warrants (the “Common Warrants”) to purchase 4,620,485 shares of Common Stock at a per share exercise price of $3.82 of warrant to accredited investors.

“Series E-1 Warrants (the “Common Warrants”) to purchase 4,620,485 shares of Common Stock at a per share exercise price of $3.82”

BNB PLUS CORP. issued 4,620,485 shares of common stock to accredited investors for $3.32 per share.

““Cash Purchasers”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “Cash Offering”), at an offering price of $3.32 per share, an aggregate of 4,620,485 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), and/or prefunded warrants in lieu”

BNB PLUS CORP. issued 3,334,471 prefunded warrants of common stock to certain accredited investors for cash equivalents of crypto-currency (or trust units or interests that that hold crypto-currency).

“3,334,471 prefunded warrants (the “Cryptocurrency Prefunded Warrants”) to purchase shares of Common Stock at a per share exercise price of $3.82”

BNB PLUS CORP. issued 3,334,471 shares of Common Stock of warrant to certain accredited investors for per share exercise price of $3.82.

“3,334,471 common stock purchase warrants (the “Cryptocurrency Common Warrants”) at a per share exercise price of $3.82”

BNB PLUS CORP. issued 4,730,178 shares of Common Stock of warrant to certain accredited investors for per share exercise price of $3.82.

“Series E Warrants (the “Common Warrants”) to purchase 4,730,178 shares of Common Stock at a per share exercise price of $3.82”

BNB PLUS CORP. issued 4,730,178 shares of common stock to certain accredited investors for U.S. dollars or the cryptocurrency stablecoin issued by Circle Internet Group, Inc. commonly referred to as "USDC".

“the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “Cash Offering”) an aggregate of 4,730,178 shares (the “Shares”) of common stock of the Company”

BNB PLUS CORP. announced a restructuring with charges of approximately $300 thousand in one-time charges affecting Applied DNA Clinical Labs (ADCL); company-wide workforce reduction (approximately 27% of headcount).

“Company’s former Chairman and Chief Executive Officer. The projected annual payroll savings is expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges related to the workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. The Company expects to incur the majority of”

Judith Murrah was elected as Chief Executive Officer, Chairperson and Director at BNB PLUS CORP..

“On June 17, 2025, the Board elected Judith Murrah, the Company’s current President, as Chief Executive Officer and as Chairperson and a member of the Board effective June 18, 2025.”

Dr. James A. Hayward retired as Chief Executive Officer, Chairman of the Board and Director at BNB PLUS CORP..

“On June 16, 2025, Dr. James A. Hayward informed Applied DNA Sciences, Inc. (the “Company”) of his intention to retire from the Company and that he will step down from his positions as Chief Executive Officer, member of the Company’s board of directors (the “Board”) and Chairman of the Board effective June 18, 2025.”

BNB PLUS CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iv)).

“May 30, 2025 (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer satisfies the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (colle”

BNB PLUS CORP.: Certificate of Incorporation amended to effect a 1-for-15 reverse stock split (effective 2025-06-02).

“At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) held on May 22, 2025, the stockholders of Applied DNA Sciences, Inc. (the “Company”) authorized the board of directors of the Company (the “Board”), in its discretion, to amend the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse split of the Company’s outstanding common stock, par value $0.001 (the “Common Stock”), at a ratio between one-for-five (1:5) and one-for-fifty (1:50), with such final ratio to be determined by the Board. The Board determined to set the reverse stock split ratio at one-for-fifteen (1:15) (the “Reverse Stock Split”) and approved the final form of the Certificate of Amendment to the Certificate of Incorporation to effectuate the Reverse Stock Split (the “Certificate of Amendment”).”

BNB PLUS CORP.: Amended certificate of incorporation to effect a 1-for-50 reverse stock split (effective 2025-03-14).

“The Certificate of Amendment will be filed with the Secretary of State of the State of Delaware on March 13, 2025, and the Reverse Stock Split will become effective in accordance with the terms of the Certificate of Amendment at 12:01 a.m. Eastern Time on Friday, March 14, 2025 (the “Effective Time”).”

BNB PLUS CORP. engaged CBIZ CPAs P.C. as its auditor.

“with the approval of the Audit Committee of the Company's Board of Directors, CBIZ CPAs P.C. was engaged as the Company's independent registered public accounting firm”

Marcum LLP resigned as auditor of BNB PLUS CORP..

“On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum LLP (“Marcum”). On January 24, 2025, Applied DNA Sciences, Inc.”

BNB PLUS CORP.: Reduced stockholder meeting quorum to one-third of outstanding shares and granted CEO authority to adjourn meetings (effective 2024-11-07).

“On November 7, 2024, the board of directors of Applied DNA Sciences, Inc. (the “Company”) adopted a certificate of amendment (the “Certificate of Amendment”) to its bylaws (the “Bylaws”). Also on November 7, 2024, a duly authorized officer of the Company executed the Certificate of Amendment, which became effective upon execution. Among other things, the Certificate of Amendment amended the Bylaws to: ● Reduce the required quorum for any meeting of stockholders to one-third (1/3) of the issued and outstanding shares entitled to vote at a meeting from a majority of the issued and outstanding shares entitled to vote at a meeting; and ● Grant the Chief Executive Officer of the Company the authority to adjourn any meeting of stockholders of the Company.”

BNB PLUS CORP. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“(the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, the Company reported stockholders’ equity of ($175,385), which was below the Stockholders’ Equity Requirement. In accordance with Nasdaq rules, the Company has 45 calendar days, or until July 1, 2024, to submit a plan to the Staff to”

BNB PLUS CORP. reported second fiscal quarter ended March 31, 2024 results: revenue approximately $930 thousand.

“reporting period. The Company will host an investor update call on June 12, 2024. Summary Second Quarter Fiscal 2024 Financial Results: ● Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter of fiscal 2023. The decrease in revenue of approximately $3.5 million was due to an”

BNB PLUS CORP.: Certificate of Amendment to effectuate a 1-for-20 reverse stock split and update CUSIP number (effective 2024-04-25).

“The Board determined to set the reverse stock split ratio at one-for-twenty (1:20) (the “Reverse Stock Split”) and approved the final form of the Certificate of Amendment to the Certificate of Incorporation to effectuate the Reverse Stock Split (the “Certificate of Amendment”).”

BNB PLUS CORP.: Reverse stock split at 1-for-20 ratio via amendment to certificate of incorporation (effective 2024-04-25).

“The Board determined to set the reverse stock split ratio at one-for-twenty (1:20) (the “Reverse Stock Split”) and approved the final form of the Certificate of Amendment to the Certificate of Incorporation to effectuate the Reverse Stock Split”

BNB PLUS CORP. entered into Warrant Amendments with certain holders valued at $0.609 per Warrant (effective 2024-04-16).

“On April 16, 2024, the Company entered into amendments to certain outstanding warrants (“Warrants”) to purchase shares of the Company’s common stock”

BNB PLUS CORP. shareholders approved To approve an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 4,000,000 shares. at the 2024-04-15 meeting.

“IV. To approve an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 4,000,000 shares. FOR AGAINST ABSTAIN BROKER NON-VOTES 4,748,305 633,432 25,825 3,850,003”

BNB PLUS CORP. shareholders approved To grant the Board of Directors discretionary authority to amend the Company’s certificate of incorporation, as amended, to effect a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Company’s Board of Di at the 2024-04-15 meeting.

“III. To grant the Board of Directors discretionary authority to amend the Company’s certificate of incorporation, as amended, to effect a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Company’s Board of Directors following the Special Meeting. FOR AGAINST ABSTAIN BROKER NON-VOTES 8,360,021 824,051 73,493 0”

BNB PLUS CORP. shareholders approved To approve, in accordance with Nasdaq Listing Rule 5635(d), the repricing of certain of our common stock purchase warrants. at the 2024-04-15 meeting.

“II. To approve, in accordance with Nasdaq Listing Rule 5635(d), the repricing of certain of our common stock purchase warrants. FOR AGAINST ABSTAIN BROKER NON-VOTES 4,826,983 541,578 39,001 3,850,003”

BNB PLUS CORP. shareholders approved To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance to certain holders of common stock purchase warrants in connection with a private placement. at the 2024-04-15 meeting.

“I. To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance to certain holders of common stock purchase warrants in connection with a private placement. FOR AGAINST ABSTAIN BROKER NON-VOTES 4,855,864 516,472 35,226 3,850,003”

BNB PLUS CORP. reported the three-month period ended December 31, 2023 results: revenue approximately $891 thousand.

“Total revenues were approximately $891 thousand for the three-month period December 31, 2023, compared to $5.3 million for the same period in the prior fiscal year.”

BNB PLUS CORP. entered into Purchase Agreements with certain institutional investors (effective 2024-01-31).

“Also on January 31, 2024, in connection with the Offering, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (each, a “Purchaser” and, collectively, the “Purchasers”).”

BNB PLUS CORP. entered into Placement Agreement with Maxim Group LLC (effective 2024-01-31).

“On January 31, 2024, Applied DNA Sciences, Inc. (“Company”) entered into a placement agency agreement (the “Placement Agreement”) with Maxim Group LLC (the “Placement Agent”)”

BNB PLUS CORP. terminated Equity Distribution Agreement with Maxim Group LLC (effective 2024-01-30).

“Effective January 30, 2024, the Company terminated the Equity Distribution Agreement by providing a notice of termination to the Agent in accordance with the terms of the Equity Distribution Agreement.”

BNB PLUS CORP. reported fourth quarter ended September 30, 2023 results: revenue approximately $780 thousand, net income $3.6 million.

“in vitro diagnostics, gene editing/therapy and adoptive cell therapy applications.” Summary Fourth Quarter Fiscal 2023 Financial Results: · Total revenues were approximately $780 thousand for the three-month period September 30, 2023, compared to $3.6 million for the same period in the prior fiscal year. The decrease in revenue of approximately $2.8 million was”

BNB PLUS CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 1, 2023, Applied DNA Sciences, Inc. (the “Company”) received written notice (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement e”

BNB PLUS CORP. entered into Equity Distribution Agreement with Maxim Group LLC valued at up to $6,397,939 (effective 2023-11-07).

“On November 7, 2023, Applied DNA Sciences, Inc. (the " Company ") entered into an Equity Distribution Agreement (the " Agreement ") with Maxim Group LLC, as sales agent (the " Agent "), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, par value $0.001 per share, in an aggregate offering price of up to $6,397,939 (the " Shares ") through the Agent.”

BNB PLUS CORP. shareholders approved Ratify appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending September 30, 2023 at the 2023-09-19 meeting.

“III. To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023. FOR AGAINST ABSTAIN 6,504,292 476,312 100,170”

BNB PLUS CORP. shareholders approved Approve amendment to 2020 Equity Incentive Plan to increase authorized shares by 3,500,000 at the 2023-09-19 meeting.

“II. To approve an amendment to the Company’s 2020 Equity Incentive Plan, to increase the number of shares of common stock authorized for issuance by an additional 3,500,000. FOR AGAINST ABSTAIN BROKER NON-VOTES 2,520,302 1,368,359 86,583 3,105,530”